Amylyx Pharmaceuticals Financials - Benzinga

Amylyx Pharmaceuticals Inc

AMLXNASDAQ

Trade with Public

Trade with Public

$21.63

-0.85-3.78%

At close: Aug 14, 5:00 PM EST

$21.50

-0.13-0.6%

After Hours: 6:03 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Amylyx Pharmaceuticals Financials

Amylyx Pharmaceuticals (AMLX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
RAmylyx Pharma Q2 EPS $(0.39) Misses $(0.36) Estimate, Cash & Equivalents $279.8M. Cash runway Expected To Fund Operations Till 2028

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 15.22 percent increase over losses of $(0.46) per share from

Benzinga Newsdesk

PRO
Amylyx Pharma Q1 EPS $(0.37), Inline, Cash, Cash Equivalents, And Short-Term Investments Were $279.8M, With Expected Cash Runway into 2028

Benzinga Newsdesk

PRO
Amylyx Pharma Q4 EPS $(0.30) Beats $(0.36) Estimate

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.9 percent. This is a 45.45 percent increase over losses of $(0.55) per share from the

Benzinga Newsdesk

Earnings Scheduled For March 3, 2026

Benzinga Insights

A Look at Amylyx Pharma's Upcoming Earnings Report

Benzinga Insights

PRO
Amylyx Pharma Q3 EPS $(0.37) Beats $(0.45) Estimate

Amylyx Pharma (NASDAQ:AMLX) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.45) by 17.04 percent. This is a 30.19 percent increase over losses of $(0.53) per share from the

Benzinga Newsdesk